By Sherri Oslick --
About
Court Report: Each week we will report briefly on recently filed
biotech and pharma cases, and a few interesting cases will be selected
for periodic monitoring.
Endo Pharmaceuticals Inc. et al. v. Actavis South Atlantic LLC
2:08-cv-03482; filed July 11, 2008 in the District Court of New Jersey
Infringement of U.S. Patent No. 5,958,456 ("Controlled Release Formulation (Albuterol)," issued September 28, 1999) following a paragraph IV certification as part of Actavis' amendment of their ANDA (adding additional dosage forms) to manufacture a generic version of Endo's Opana® ER (oxymorphone hydrochloride, used to treat moderate to severe pain in patients requiring continuous, around-the-clock opioid treatment for an extended period of time). View the complaint here. As reported here, Endo has previously asserted this patent against Actavis in response to Actavis' initial paragraph IV certification.
Sanofi-Aventis et al. v. Sun Pharmaceutical Industries Ltd. et al.
1:08-cv-06286; filed July 11, 2008 in the Southern District of New York
Infringement of U.S. Patent Nos. 4,847,256 ("4,5-dihydro and 4,5,6,7-tetrahydropyrazolo(1,5-A)-pyrimidines" issued July 11, 1989) and 6,429,210 ("Polymorphic Clopidogrel Hydrogenesulphate Form," issued August 6, 2002) following a paragraph IV certification as part of Sun's filing of an ANDA to manufacture a generic version of Sanofi-Aventis' and Bristol-Myers Squibb's Plavix® (clopidogrel bisulfate, used for the reduction of atherothrombotic events). View the complaint here.
AstraZeneca Pharmaceuticals LP et al. v. Teva Pharmaceuticals USA
1:08-cv-00426; filed July 10, 2008 in the District Court of Delaware
Infringement of U.S. Patent No. RE37,314 ("Pyrimidine Derivatives," issued August 7, 2001) following a paragraph IV certification as part of Teva's filing of an amended ANDA to manufacture a generic version of AstraZeneca's Crestor® (rosuvastatin calcium, used to treat high cholesterol). View the complaint here.
Comments